[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"non-segmental-vitiligo\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:non-segmental-vitiligo":54},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,40,73,95,118,139,168,190,213],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100644043","phase-2-a-study-to-learn-how-safe-act-777991-is-and-how-well-it-works-in-adults-with-non-segmental-vitiligo-100644043",false,"NCT07667569","A Study to Learn How Safe ACT-777991 is and How Well it Works in Adults With Non-segmental Vitiligo","A Phase 2a, Proof of Concept, Multicenter, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial to Assess the Efficacy and Safety of ACT-777991 in Adults With Non-segmental Vitiligo","Inclusion Criteria:\n\n* Clinical diagnosis of either active or stable non segmental vitiligo for at least 3 months prior to Screening and meet all the following criteria:\n\n  * F-VASI score ≥ 0.3 based on BICR at Screening.\n  * T-VASI score ≥ 5 based on investigator assessment at Screening and Randomization.\n  * Total body surface area (BSA) involvement, including the face, ≤ 50% based on investigator assessment at Screening and Randomization.\n* Participants must agree not to use therapeutic agents and procedures to treat vitiligo from Screening until Participant Last Visit.\n\nExclusion Criteria:\n\n* Clinical diagnosis of other forms of vitiligo (e.g., segmental) or other hypo- or depigmentation disorders (e.g., piebaldism, leukoderma, Vogt-Koyanagi-Harada disease, malignancy-induced hypopigmentation).\n* Any autoimmune disease, except adequately treated thyroid disease.\n* History of systemic immunotherapy treatment, including JAK inhibitors, for any inflammatory disease in the 12 months prior to Randomization.\n* History of topical JAK inhibitors for any inflammatory disease in the 6 weeks prior to Screening.\n* Use of laser or light-based treatment (phototherapy), including tanning beds, in the 8 weeks prior to Screening.\n* eGFR \\\u003C 90 mL\u002Fmin\u002F1.73 m2, defined by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation, at Screening.","ALL","18 Years","65 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The purpose of this clinical trial is to learn how well ACT-777991 works, how safe it is and how well it is tolerated by adults with non-segmental vitiligo.\n\nThe main question this clinical trial aims to answer is:\n\n• Can ACT-777991 help return color to the skin of the face of adults with non-segmental vitiligo?\n\nResearchers will compare ACT-777991 to placebo (a look-alike inactive treatment that contains no medicine) to see if ACT-777991 works to treat non-segmental vitiligo.\n\nTrial participants will:\n\n* Take the trial intervention (either ACT-777991 or placebo) daily for 24 weeks.\n* Visit the clinic 7 times for check-up and tests.",[27],"Non-Segmental Vitiligo","NOT_YET_RECRUITING","2026-06-24",{"date":31,"type":32},"2026-06-25","ACTUAL",{"date":34,"type":21},"2026-06",{"date":36,"type":21},"2027-07",{"name":38,"class":39},"Idorsia Pharmaceuticals Ltd.","INDUSTRY",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100626095","phase-2-a-phase-iib-dose-ranging-study-to-assess-the-efficacy-and-safety-of-gia632-in-participants-with-non-segmental-vitiligo-100626095","NCT07431177","A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo","A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Phase IIb Study to Assess the Efficacy and Safety of GIA632 in Adult Participants With Non-segmental Vitiligo Followed by an Extension Period","VITESS","Inclusion Criteria:\n\n* Signed informed consent must be obtained prior to participation in the study\n* Male or female as assigned at birth ≥ 18 years of age at the time of screening\n* Individuals with a diagnosis of non-segmental vitiligo and confirmation of diagnosis through physical examination by the investigator\n* Non-segmental vitiligo, as assessed at screening, as\n* ≥ 0.5% Body Surface Area (BSA) on the face and F-VASI score ≥ 0.5\n* ≥ 3% BSA on non-facial areas (minimum of 3% should be calculated in addition to hands and feet) and T-VASI score = 3 to 60\n\nExclusion Criteria:\n\n* Individuals unable or unwilling to follow the study procedures and\u002For to complete the study-related questionnaires\n* Presence of segmental or mixed vitiligo, or other skin comorbidities that may interfere with study assessments (e.g., hypopigmented mycosis fungoides, genetic diseases with pigmentary aberrations \\[such as piebaldism, Waardenburg, etc.\\], chemical- or druginduced leukoderma, etc.)\n* Previous exposure to biologic drugs directly targeting IL-15 or IL-15 receptors\n* Individual who previously attempted or completed depigmentation therapy for NSV\n* Use of prohibited medication \\& treatments. Other protocol-defined inclusion\u002Fexclusion criteria may apply","99 Years",{"count":50,"type":21},210,[24],"The main purpose of this multicenter, randomized, double-blind, placebo-controlled Phase 2b study is to investigate the safety and efficacy of GIA632 in participants with NSV and to identify the optimal dose to be promoted into the confirmatory Phase 3 program.",[54],"Non-segmental Vitiligo",[56,57,58,59,60,61],"Phase 2b","interventional","vitiligo","efficacy","safety","dose ranging","RECRUITING","2026-06-18",{"date":65,"type":32},"2026-06-22",{"date":67,"type":32},"2026-03-09",{"date":69,"type":21},"2030-01-28",{"name":71,"class":39},"Novartis Pharmaceuticals",33,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":82,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":94},"100610103","phase-2-phase-2-study-to-evaluate-ei-001-in-non-segmental-vitiligo-patients-100610103","NCT07223229","Phase 2 Study to Evaluate EI-001 in Non-segmental Vitiligo Patients","A Phase 2, Randomized, Double-Blind, Placebo-controlled Proof-of-Concept Study to Evaluate the Efficacy and Safety of EI-001 in Patients With Nonsegmental Vitiligo","Inclusion Criteria:\n\n* Able to understand and voluntarily sign the informed consent form (ICF).\n* Male or female, aged 18-65 years at the time of consent.\n* BMI 18-38 kg\u002Fm² and weight ≥ 40 kg at consent. Clinically diagnosed non-segmental vitiligo (NSV) for at least 3 months, and meets one of the following:\n* Inadequate response to approved treatments:\n* Topical therapy (e.g., corticosteroids, calcineurin inhibitors, or JAK inhibitors) ≥ 3 months,\n* Phototherapy ≥ 6 months, or Oral therapy (e.g., corticosteroids, calcineurin inhibitors) ≥ 3 months.\n* Or unable to use these treatments due to contraindications, intolerance, or unsuitability.\n* Depigmentation extent meeting all of the following:\n\nFacial BSA (F-BSA) ≥ 0.5%, Facial VASI (F-VASI) ≥ 0.5, Total BSA (T-BSA) between 5% and 60%, Total VASI (T-VASI) ≥ 5.\n\n* Agree to discontinue all vitiligo treatments from screening until final follow-up.\n* If not previously vaccinated against zoster, agree to complete vaccination before Day 1.\n* Contraception\n* Not applicable to females of non-childbearing potential (surgically sterile or postmenopausal ≥12 months, confirmed by FSH at screening).\n\nExclusion Criteria:\n\n* Non-eligible skin conditions: Other types of vitiligo (e.g., segmental) or other depigmentation disorders (e.g., piebaldism, leprosy, post-inflammatory hypopigmentation, tinea versicolor, etc.), or ≥30% leukotrichia on face or body.\n* Psychiatric risk\n* Recent vitiligo treatments\n* Surgical treatments or depigmenting agents (e.g., monobenzone)\n* High-dose steroids\n* Pregnancy or lactation\n* Abnormal Medical conditions\n* Prohibited prior therapies\n* Cardiac abnormalities\n* Abnormal chest X-ray\n* Renal impairment\n* Clinically significant abnormal laboratory results at screening, per investigator judgment.\n* Viral infections:\n* Hypersensitivity: Known allergy or severe reaction to EI-001 or its excipients.\n* Compliance concerns: Any condition that would make it difficult for the subject to follow the study schedule, receive treatment, attend visits, or could interfere with study objectives, data interpretation, or participant safety.",{"count":81,"type":21},45,[24],"The primary purpose of this study is to evaluate whether the drug EI-001 can help improve vitiligo symptoms. EI-001 is a novel antibody drug that affects the immune system to decrease uncontrolled inflammation. EI-001 has been investigated in human cell cultures, animal studies, and in a Phase 1 healthy volunteer study. The results so far show that EI-001 is a tolerable and potential new treatment for immune diseases such as vitiligo.",[54],"2026-06-03",{"date":87,"type":32},"2026-06-05",{"date":89,"type":32},"2025-12-30",{"date":91,"type":21},"2027-09-30",{"name":93,"class":39},"Elixiron Immunotherapeutics (Hong Kong) Ltd.",6,{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":102,"enrollmentInfo":103,"targetDuration":4,"studyType":22,"phases":105,"briefSummary":106,"conditions":107,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":117},"100612285","phase-2-a-trial-of-shr0302-tablets-and-shr0302-base-gel-in-patients-with-non-segmental-vitiligo-100612285","NCT07251595","A Trial of SHR0302 Tablets and SHR0302 Base Gel in Patients With Non-segmental Vitiligo","A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of SHR0302 Tablets as Single Therapy or in Combination With SHR0302 Base Gel in the Treatment of Patients With Non-segmental Vitiligo","Inclusion Criteria:\n\n1. Sign the informed consent form before the clinical trial.\n2. On the day of signing the informed consent form, the age must be between 18 and 75 years old (inclusive), and it can be either male or female.\n3. The subjects and their partners had no intention of having children during the study period and within one month after the administration of the drug, did not donate sperm or eggs, and voluntarily adopted effective contraceptive measures. The serum pregnancy test results of the female subjects must be negative and they must not be in the lactation period.\n4. During the screening process, it was clinically diagnosed as non-segmental vitiligo.\n5. Throughout the entire research process, the participants agreed to stop using all treatments related to vitiligo as well as any cosmetic products with therapeutic effects.\n\nExclusion Criteria:\n\n1. Subjects diagnosed with segmental, mixed or undifferentiated vitiligo; or subjects previously diagnosed with other skin pigmentation disorders.\n2. When the facial skin lesions caused by vitiligo cover more than 33% of the area with white hair.\n3. During the screening period or at the baseline, there were other active skin lesions or skin infections that might interfere with the use of the study drug or the evaluation of the drug's efficacy.\n4. Subjects with a history of related infections\u002Fcommunicable diseases or infection\u002Fcontagion history.\n5. Known or suspected history of immunosuppression.\n6. Tuberculosis (TB) or latent tuberculosis infection.\n7. Positive for human immunodeficiency virus antibody HIV-Ab, positive for syphilis-specific antibody, positive for hepatitis C virus antibody HCV-Ab, or hepatitis B virus (HBV) infection.\n8. Subjects who have malignant tumors or have a history of malignant tumors.\n9. Abnormal thyroid function, with a history of thrombotic diseases within the previous 12 months, and having experienced a cardiovascular or cerebrovascular event that required hospitalization within the previous 12 months.\n10. There are serious abnormalities in the cardiovascular, mental, renal, liver, immune, gastrointestinal, urogenital, nervous, skeletal-muscular, skin, sensory, endocrine or hematological systems.\n11. Pregnant women, lactating women, or female participants who plan to become pregnant during the study period.\n12. Those who are known to be allergic to the test drug or any component of the test drug.","75 Years",{"count":104,"type":21},176,[24],"The study is being conducted to evaluate the efficacy, and safety of SHR0302 tablets as single therapy or in combination with SHR0302 Base gel for patients with non-segmental vitiligo.",[54],"2026-02-14",{"date":110,"type":32},"2026-02-18",{"date":112,"type":32},"2025-12-05",{"date":114,"type":21},"2027-09",{"name":116,"class":39},"Jiangsu HengRui Medicine Co., Ltd.",1,{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":102,"enrollmentInfo":125,"targetDuration":4,"studyType":22,"phases":127,"briefSummary":128,"conditions":129,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":117},"100606191","phase-2-efficacy-and-safety-phase-ii-study-of-vc005-tablets-in-subjects-with-non-segmental-vitiligo-100606191","NCT07172347","Efficacy and Safety Phase II Study of VC005 Tablets in Subjects With Non-segmental Vitiligo","A Multicenter, Randomized, Double-blind, Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Tablets in Subjects With Non-segmental Vitiligo","Inclusion Criteria:\n\n* The subject understands and voluntarily signs the informed consent form (ICF) and is willing and able to comply with the study protocol.\n* The subject is between 18 and 70 years of age (including borderline values) , regardless of gender.\n\nExclusion Criteria:\n\n* Pregnant or lactating women, or subjects with pregnancy or lactation plans during the study period.\n* All hair in the vitiligo area on the face is white.\n* Those who are known or suspected to be allergic to the main ingredients and excipients of VC005 or similar drugs.\n* Subjects who have previously received depigmentation treatment.\n* Subjects who have received experimental drug administration or participated in device clinical trials within the first month or 5 half lives (whichever is longer) prior to randomization.",{"count":126,"type":21},120,[24],"This clinical trial is a multicenter, randomized, double-blind, controlled phase II clinical study",[54],"2025-12-29",{"date":132,"type":32},"2026-01-02",{"date":134,"type":32},"2025-10-31",{"date":136,"type":21},"2027-08-30",{"name":138,"class":39},"Jiangsu vcare pharmaceutical technology co., LTD",{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":4,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":16,"minAge":146,"maxAge":147,"enrollmentInfo":148,"targetDuration":4,"studyType":22,"phases":150,"briefSummary":152,"conditions":153,"keywords":155,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":117},"100592326","phase-4-comparison-of-needling-and-microneedling-plus-phototherapy-in-localized-vitiligo-patients-100592326","NCT06991972","Comparison of Needling and Microneedling Plus Phototherapy in Localized Vitiligo Patients","Puncture to Repigment: A Comparative Analysis Of Needling vs. Microneedling Along With NBUVB in Treatment of Non-Segmental Vitiligo","Inclusion Criteria:\n\n* Both male and female\n* Age 15-60 years\n* Patients having vitiligo for more than 1 year\n\nExclusion Criteria:\n\n* Patients with tendency of keloid formation or hypertrophic scarring\n* Patients with any bleeding disorder, coagulation defect or using anti platelets\n* Any local infection at the treatment site\n* Patients who had received systemic therapy in last 6 months","15 Years","60 Years",{"count":149,"type":21},80,[151],"PHASE4","This randomized controlled trial aims to compare the efficacy of needling versus microneedling, both followed by narrowband UVB therapy, in achieving repigmentation in patients with localized stable non-segmental vitiligo.",[154,54],"Vitiligo",[58,156,157],"needling","microneedling","2025-08-25",{"date":160,"type":32},"2025-09-02",{"date":162,"type":32},"2025-03-01",{"date":164,"type":21},"2025-08-31",{"name":166,"class":167},"Khyber Teaching Hospital","OTHER",{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":172,"acronym":4,"eligibilityCriteria":173,"healthyVolunteers":11,"sex":16,"minAge":174,"maxAge":17,"enrollmentInfo":175,"targetDuration":4,"studyType":22,"phases":177,"briefSummary":178,"conditions":179,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":117},"100601035","phase-2-an-open-label-single-center-proof-of-concept-study-evaluating-the-efficacy-of-roflumilast-foam-03-in-pediatric-patients-with-non-segmental-vitiligo-nsv-100601035","NCT07105254","An Open-label Single Center, Proof of Concept Study Evaluating the Efficacy of Roflumilast Foam 0.3% in Pediatric Patients With Non-Segmental Vitiligo (NSV)","Inclusion Criteria:\n\n1. Male or female subjects aged 2 years but less than 18 years\n2. Pediatric and adolescent subjects: Informed consent of parent(s) or legal guardian, and, if age appropriate, assent by the subjects, as required by local laws.\n3. Diagnosis of non-segmental vitiligo based on clinical history and dermatology examination for at least 3 months.\n4. Diagnosis of non-segmental vitiligo with the following:\n\n   1. BSA affected \\\u003C 10% AND\n   2. At least 0.5% BSA affected on the face. AND\n   3. Pigmented hair within some of the areas of vitiligo on the face\n5. In good health as judged by the Investigator, based on the medical history, and dermatology examination.\n6. Subjects and parent(s)\u002Flegal guardian (s) are considered reliable and capable of adhering to the Protocol and visit schedule, according to the judgment of the Investigator.\n\nExclusion Criteria:\n\n1. Subjects with any serious medical condition or physical examination abnormality that would prevent study participation or place the subject at significant risk, as judged by the Investigator.\n2. Subjects with known or suspected:\n\n   1. Severe renal insufficiency\n   2. Moderate to severe hepatic disorders (Child-Pugh B or C)\n   3. Subjects who cannot discontinue prohibited medications and treatments prior to the Baseline visit and during the study, including (any biologic or experimental therapy within 12 weeks (or 5 half-lives), phototherapy within 4 weeks, immunomodulating treatments within 4 weeks, or topical treatments within 1 week.\n3. Subjects who are unwilling to refrain from using a tanning bed or other artificial light emitting devices (LEDs) for 4 weeks prior to Baseline\u002FDay 1 and during the study.\n4. Subjects with diagnosis of other forms of vitiligo (e.g. Segmental), other differential diagnosis of vitiligo or other skin depigmentation disorders (e.g. Piedbaldism, pityriasis alba, leprosy, post-inflammatory hypopigmentation, progressive macule hypomelanosis, nevus anemicus, chemical leukoderma and tinea versicolor) that would interfere with the evaluations of the effect of the study medication, as determined by the Investigator.\n5. Subjects with known genetic dermatological conditions that overlap with non-segmental vitiligo.\n6. Known allergies to excipients in Roflumilast foam (petrolatum, isopopyl palmitate, methylparaben, propylparaben, diethylene glycol monomethyl ether, hexylene glycol, cetylseteary alcohol, dicetyl phosphase and ceteth-10 phosphate)\n7. Subjects who cannot discontinue systemic CYP3A4 inhibitors or dual inhibitors that inhibit both CYP3A4 and CYP1A2 simultaneously (e.g. Erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine)\n8. Subjects who have received oral roflumilast (Daxas®, Daliresp®) within 4 weeks prior to Baseline\u002FDay 1.\n9. Females who are pregnant, wishing to become pregnant during the study, or are breast feeding.\n10. Previous treatment with Roflumilast cream or foam for vitiligo in the past 3 months.\n11. Parent (s)\u002Flegal guardians (s) who are unable to communicate, read, or understand the local language (s). Subjects who are unable to communicate, read or understand the local language, or who display another condition, which in the Investigator's opinion, makes them unsuitable for clinical study participation.\n12. Subjects who are family members of the clinical study site, clinical study staff, or sponsor, or family members of enrolled subjects living in the same house.","2 Years",{"count":176,"type":21},20,[24],"An open-label single center, proof of concept study evaluating the efficacy of Roflumilast foam 0.3% in pediatric subjects with Non-Segmental Vitiligo (NSV)",[54],"2025-08-05",{"date":182,"type":32},"2025-08-08",{"date":184,"type":21},"2025-08-01",{"date":186,"type":21},"2026-06-15",{"name":188,"class":189},"Derm Texas, PLLC","NETWORK",{"id":191,"slug":192,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":4,"eligibilityCriteria":196,"healthyVolunteers":11,"sex":16,"minAge":197,"maxAge":102,"enrollmentInfo":198,"targetDuration":4,"studyType":22,"phases":200,"briefSummary":202,"conditions":203,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":205,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":81},"100596603","phase-2-icp-332-in-subjects-with-non-segmental-vitiligo-100596603","NCT07047612","ICP-332 in Subjects With Non-segmental Vitiligo","A Phase II\u002FIII Randomized, Double-blind, Placebo-controlled, Parallel Group, Adaptive Design, Multi-center Study to Evaluate the Efficacy and Safety of ICP-332 in Subjects With Non-segmental Vitiligo","Inclusion Criteria:\n\n1. Male or female subjects aged ≥18 years and ≤75 years (Phase II portion). Male or female subjects ≥12 years of age and ≤75 years of age, adolescent subjects must weigh ≥40 kg (Phase III portion).\n2. Eligible subjects must meet all of the following criteria at screening and baseline:\n\n   1. The clinical diagnosis was non-segmental vitiligo for at least 3 months.\n   2. Involvement of BSA≥5%.\n   3. Facial involvement BSA≥0.5%.\n   4. F-VASI≥0.5 and T-VASI between 5 and 50.\n   5. Active or stable non-segmental vitiligo was present at both screening and baseline visits.\n3. Women of childbearing potential (WOCBP) and Men must agree to contraception.\n4. Before beginning any screening or study specific procedures, subjects must voluntarily sign informed consent.\n\nExclusion Criteria:\n\n1. Any of the following vitiligo related medical conditions and other skin diseases\u002Fconditions.\n\n   a) Subjects had other types of vitiligo (including but not limited to segmental vitiligo and mixed vitiligo) that did not meet the criteria for active or stable vitiligo described in Inclusion criteria 2.\n2. History of any clinically major diseases, with the exception of vitiligo.\n3. Pregnant or breastfeeding females.\n4. The investigator considers that the subject is not suitable for participation in this study for any reason.","12 Years",{"count":199,"type":21},603,[24,201],"PHASE3","This a phase II\u002FIII randomized, double-blind, placebo-controlled, parallel group, adaptive design, multi-center study to evaluate the efficacy and safety of ICP-332 in subjects with non-segmental vitiligo。The study consisted an phase 2 part and an phase 3 part.",[204],"Non Segmental Vitiligo",{"date":206,"type":32},"2025-08-07",{"date":208,"type":32},"2025-05-09",{"date":210,"type":21},"2029-04",{"name":212,"class":39},"Beijing InnoCare Pharma Tech Co., Ltd.",{"id":214,"slug":215,"hasResults":11,"nctId":216,"briefTitle":217,"officialTitle":218,"acronym":4,"eligibilityCriteria":219,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":220,"targetDuration":4,"studyType":22,"phases":222,"briefSummary":223,"conditions":224,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":117},"100555411","phase-2-a-study-to-evaluate-the-efficacy-and-safety-of-syhx1901-tablet-in-non-segmental-vitiligo-patients-100555411","NCT06511739","A Study to Evaluate the Efficacy and Safety of SYHX1901 Tablet in Non-segmental Vitiligo Patients","A Phase 2 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of SYHX1901 Tablet in Non-segmental Vitiligo Patients","Inclusion Criteria:\n\n1. Willing to sign an ICF, able to comprehend and comply with the study procedures.\n2. Male or female subjects aged 18 to 65，inclusive.\n3. Subjects with a clinical diagnosis of non-segmental vitiligo.\n4. Agree to stop all other treatments for vitiligo during the study period.\n5. Women of child-bearing potential must have a negative serum pregnancy test within 3 days prior to the first study agent administration.\n\nExclusion Criteria:\n\n1. Diagnosed as other active depigmentation disease.\n2. At screening or baseline visits, subject exhibits active inflammatory dermatologic disease or symptoms that in the opinion of investigators would interfere of vitiligo evaluation or response to treatment.\n3. Uncontrolled thyroid function at screening as determined by the investigator.\n4. Use of permanent depigmentation treatment or skin grafts.\n5. Use of phototherapy, topical or systemic treatments within certain time frame prior to Day1.\n6. Have active bacterial\u002Fvirus\u002Fother pathogens infection or infestation that require medical intervention.\n7. Have progressive or uncontrolled systemic disease, or other concomitant chronic disease that the investigators believe unsuitable to participate the study.\n8. History of alcohol and drug abuse within one year prior to screening; History of neurological or mental disorders with diagnosis records, such as severe depression, suicidal tendencies, epilepsy, dementia, etc.\n9. Have any other reasons determined by the investigator that the subject is not eligible for the study.",{"count":221,"type":21},144,[24],"A 52-Week Study of SYHX1901 tablet in Adults with non-segmental vitiligo.",[54],"2024-07-15",{"date":227,"type":32},"2024-07-22",{"date":229,"type":32},"2024-05-27",{"date":231,"type":21},"2025-10-01",{"name":233,"class":39},"CSPC Ouyi Pharmaceutical Co., Ltd."]